Menu
 
Research menu
Jump to menu

Publications:  Prof Jude Fitzgibbon

Jakobsen JS, Laursen LG, Schuster MB, Pundhir S, Schoof E, Ge Y, d¿Altri T, Vitting-Seerup K et al.(2019). Mutant CEBPA directly drives the expression of the targetable tumor-promoting factor CD73 in AML. Science Advances vol. 5, (7) eaaw4304-eaaw4304.
10.1126/sciadv.aaw4304
Tawana K, Rio-Machin A, Preudhomme C, Fitzgibbon J(2017). Familial CEBPA-mutated acute myeloid leukemia. Seminars in hematology vol. 54, (2) 87-93.
10.1053/j.seminhematol.2017.04.001
Tawana K, Rio-Machin A, Preudhomme C, Fitzgibbon J(2017). Familial CEBPA-mutated acute myeloid leukemia. SEMINARS IN HEMATOLOGY vol. 54, (2) 87-93.
10.1053/j.seminhematol.2017.04.001
Noerenberg D, Mansouri L, Young E, Mareike F, Abdulla M, Asmar F, Gonzalez-Farre B, Anna T et al. (2016). NFKBIE Deletions: A Novel Marker of Clinical Aggressiveness in Primary Mediastinal B-Cell Lymphoma. BLOOD. vol. 128,
Stunnenberg HG, Hirst M, Abrignani S, Adams D, de Almeida M, Altucci L, Amin V, Amit I et al.(2016). The International Human Epigenome Consortium: A Blueprint for Scientific Collaboration and Discovery. Cell vol. 167, (5) 1145-1149.
10.1016/j.cell.2016.11.007
Araf S, Korfi K, Rahim T, Davies A, Fitzgibbon J(2016). Advances in the molecular diagnosis of diffuse large B-cell lymphoma in the era of precision medicine. Expert Rev Mol Diagn vol. 16, (10) 1093-1102.
10.1080/14737159.2016.1235974
Araf S, Fitzgibbon J(2016). Pediatric-type FL: Simply different. Blood vol. 128, (8) 1030-1031.
10.1182/blood-2016-07-725002
Ripperger T, Tawana K, Kratz C, Schlegelberger B, Fitzgibbon J, Steinemann D(2016). Clinical utility gene card for: Familial platelet disorder with associated myeloid malignancies. EUROPEAN JOURNAL OF HUMAN GENETICS vol. 24, (8)
10.1038/ejhg.2015.278
Tawana K, Fitzgibbon J(2016). Inherited DDX41 mutations: 11 genes and counting. Blood vol. 127, (8) 960-961.
10.1182/blood-2016-01-690909
Noerenberg D, Frick M, Couronne L, Lenze D, Baldus CD, Bastard C, Okosun J, Fitzgibbon J et al. (2015). NFKBIE MUTATIONS OCCUR IN 15% OF GCB DLBCL AND IN VARIOUS OTHER LYMPHOID MALIGNANCIES. HAEMATOLOGICA. vol. 100, 549-549.
Rohatiner AZS, Smith ML, Spinelli O, Rambaldi A, Bassan R, di Bona E, Rodeghiero F, Raimondi R et al.(2014). Myeloblative therapy with autologous haematopoietic stem cell support as consolidation of first remission in acute myeloid leukaemia - very long follow-up. BRITISH JOURNAL OF HAEMATOLOGY vol. 167, (5) 724-726.
10.1111/bjh.13055
Bouska A, McKeithan TW, Deffenbacher KE, Lachel C, Wright GW, Iqbal J, Smith LM, Zhang W et al.(2014). Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma. BLOOD vol. 123, (11) 1681-1690.
10.1182/blood-2013-05-500595
Mutsaers PGNJ, van de Loosdrecht AA, Tawana K, Bödör C, Fitzgibbon J, Menko FH(2013). Highly variable clinical manifestations in a large family with a novel GATA2 mutation. Leukemia vol. 27, (11) 2247-2248.
10.1038/leu.2013.105
Gertner-Dardenne J, Fauriat C, Orlanducci F, Thibult M-L, Pastor S, Fitzgibbon J, Bouabdallah R, Xerri L et al.(2013). The co-receptor BTLA negatively regulates human V gamma 9V delta 2 T-cell proliferation: a potential way of immune escape for lymphoma cells. BLOOD vol. 122, (6) 922-931.
10.1182/blood-2012-11-464685
Green CL, Tawana K, Hills RK, Bödör C, Fitzgibbon J, Inglott S, Ancliff P, Burnett AK et al.(2013). GATA2 mutations in sporadic and familial acute myeloid leukaemia patients with CEBPA mutations. Br J Haematol vol. 161, (5) 701-705.
10.1111/bjh.12317
Bouska A, McKeithan T, Deffenbacher KE, Lachel C, Wright GW, Iqbal J, Smith LM, Liu Z et al. (2012). Genetic Abnormalities in Follicular Lymphoma and Transformed Follicular Lymphoma. BLOOD. vol. 120,
Quintana-Bustamante O, Smith SL-L, Griessinger E, Reyal Y, Vargaftig J, Lister TA, Fitzgibbon J, Bonnet D(2012). Overexpression of wild-type or mutants forms of CEBPA alter normal human hematopoiesis. LEUKEMIA vol. 26, (7) 1537-1546.
10.1038/leu.2012.38
Bödör C, Renneville A, Smith M, Charazac A, Iqbal S, Etancelin P, Cavenagh J, Barnett MJ et al.(2012). Germ-line GATA2 p.THR354MET mutation in familial myelodysplastic syndrome with acquired monosomy 7 and ASXL1 mutation demonstrating rapid onset and poor survival. Haematologica vol. 97, (6) 890-894.
10.3324/haematol.2011.054361
Leich E, Zamo A, Horn H, Haralambieva E, Puppe B, Gascoyne RD, Chan W-C, Braziel RM et al.(2011). MicroRNA profiles of t(14;18)-negative follicular lymphoma support a late germinal center B-cell phenotype. Blood vol. 118, (20) 5550-5558.
10.1182/blood-2011-06-361972
Fitzgibbon J (2011). A Molecular Portrait of Follicular Lymphoma. EUROPEAN JOURNAL OF CANCER. vol. 47, S33-S33.
10.1016/S0959-8049(11)70349-5
Stevens J, Waters R, Sieniawska C, Kassam S, Montoto S, Fitzgibbon J, Rohatiner A, Lister A et al.(2011). Serum selenium concentration at diagnosis and outcome in patients with haematological malignancies. Br J Haematol vol. 154, (4) 448-456.
10.1111/j.1365-2141.2011.08744.x
Montoto S, Fitzgibbon J(2011). Transformation of indolent B-cell lymphomas. J Clin Oncol vol. 29, (14) 1827-1834.
10.1200/JCO.2010.32.7577
Langabeer SE, Owen CJ, McCarron SL, Fitzgibbon J, Smith OP, O'Marcaigh A, Browne P(2010). A novel RUNX1 mutation in a kindred with familial platelet disorder with propensity to acute myeloid leukaemia: male predominance of affected individuals. Eur J Haematol vol. 85, (6) 552-553.
10.1111/j.1600-0609.2010.01513.x
Wrench D, Montoto S, Fitzgibbon J(2010). Molecular signatures in the diagnosis and management of follicular lymphoma. Curr Opin Hematol vol. 17, (4) 333-340.
10.1097/MOH.0b013e328338ccab
Ghazaly E, Smith P, Quentmeier H, Drexler H, Iqbal S, Taussig D, Young B, Lister A et al. (2010). ACCUMULATION OF 2-HYDROXYGLUTARATE (2-HG) IN NORMAL KARYOTYPE AML PATIENTS WITH IDH1 MUTATION. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL. vol. 95, 20-20.
Langabeer SE, Owen CJ, McCarron SL, Fitzgibbon J, O'Marcaigh A, Browne P (2010). A novel RUNX1 mutation in an Irish kindred with familial platelet disorder with propensity to acute myeloid leukaemia. BRITISH JOURNAL OF HAEMATOLOGY. vol. 149, 73-73.
Owen C, Fitzgibbon J, Paschka P(2010). The clinical relevance of Wilms Tumour 1 (WT1) gene mutations in acute leukaemia. HEMATOL ONCOL vol. 28, (1) 13-19.
10.1002/hon.931
Fitzgibbon J (2009). The Molecular Pathogenesis of Follicular Lymphoma. JOURNAL OF MEDICAL GENETICS. vol. 46, S24-S24.
Leich E, Salaverria I, Bea S, Zettl A, Wright G, Moreno V, Gascoyne RD, Chan WC et al.(2009). Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterations. BLOOD vol. 114, (4) 826-834.
10.1182/blood-2009-01-198580
Oke A, Pearce D, Wilkinson RW, Crafter C, Odedra R, Cavenagh J, Fitzgibbon J, Lister AT et al.(2009). AZD1152 Rapidly and Negatively Affects the Growth and Survival of Human Acute Myeloid Leukemia Cells In vitro and In vivo. CANCER RES vol. 69, (10) 4150-4158.
10.1158/0008-5472.CAN-08-3203
Fitzgibbon J, Gale R, Hills R, Virappane P, Burnett A, Lister TA, Linch D(2009). Comparing Apples and Oranges in Normal Karyotype Acute Myeloid Leukemia REPLY. J CLIN ONCOL vol. 27, (3) 474-476.
10.1200/JCO.2008.19.4894
Owen CJ, Toze CL, Koochin A, Forrest DL, Smith CA, Stevens JM, Jackson SC, Poon M-C et al.(2008). Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy. Blood vol. 112, (12) 4639-4645.
10.1182/blood-2008-05-156745
Virappane P, Gale R, Hills R, Kakkas I, Summers K, Stevens J, Allen C, Green C et al. (2008). Mutation of the Wilms' Tumor 1 Gene Is a Poor Prognostic Factor Associated With Chemotherapy Resistance in Normal Karyotype Acute Myeloid Leukemia: The United Kingdom Medical Research Council Adult Leukaemia Working Party. JOURNAL OF CLINICAL ONCOLOGY. vol. 26, 5429-5435.
10.1200/JCO.2008.16.0333
Deffenbacher KE, Wright G, Iqbal J, Geng HM, O'Shea D, Lister TA, Fitzgibbon J, Fu K et al. (2008). Genetic Abnormalities Involved in the Development and Progression of Follicular Lymphoma. BLOOD. vol. 112, 714-714.
Yang YW, Wrench DJ, Lister TA, Fitzgibbon J (2008). Recurrent Chromosomal Intermingling Interactions at the BCL2 Locus in T(14;18) +Ve and -Ve Cell Lines. BLOOD. vol. 112, 713-713.
Quintana-Bustamante O, Smith SLL, Fitzgibbon J, Bonnet D (2008). Role of Different C/EBP alpha Mutations in AML Transformation. BLOOD. vol. 112, 484-484.
Stevens JM, Juliger S, Summers K, Fitzgibbon J, Lister TA, Joel SP (2008). METHYLSELENINIC ACID DEMONSTRATES ANTI-LEUKAEMIC ACTIVITY AND SENSITISES AML CELLS TO THE EFFECTS OF CYTOTOXIC AGENTS BY INITIATING THE UNFOLDED PROTEIN RESPONSE. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL. vol. 93, 115-116.
Owen C, Virappane P, Alikian M, Stasevich I, Summers K, Lillington D, Bonnet D, Burnett A et al.(2008). WTX is rarely mutated in acute myeloid leukemia. HAEMATOL-HEMATOL J vol. 93, (6) 947-948.
10.3324/haematol.12509
Owen CJ, Toze CJ, Forrest DL, Macheta A, Smith CA, Barnett MJ, Yin JAL, Lister TA et al.(2008). Should patients with myelodysplasia and/or acute myeloid leukemia (MDS/AML) be screened for inherited runx1 mutations prior to sibling donor allografting?. ANN HEMATOL vol. 87, S11-S11.
Owen C, Barnett M, Fitzgibbon J(2008). Familial myelodysplasia and acute myeloid leukaemia--a review. Br J Haematol vol. 140, (2) 123-132.
10.1111/j.1365-2141.2007.06909.x
Virappane P, Gale RE, Hills R, Kakkas I, Summers K, Stevens J, Green C, Allen C et al. (2007). Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemoresistance in normal karyotype acute myeloid leukemia. BLOOD. vol. 110, 113A-113A.
Owen CJ, Yin JAL, Toze CJ, Forrest DL, Macheta A, Smith CA, Barnett MJ, Lister TA et al. (2007). Should patients with myelodysplasia and/or acute myeloid leukemia (MDS/AML) be screened for inherited RUNX1 mutations prior to sibling donor allografting?. BLOOD. vol. 110, 336B-336B.
10.1182/blood.V110.11.5027.5027
Jüliger S, Goenaga-Infante H, Lister TA, Fitzgibbon J, Joel SP(2007). Chemosensitization of B-cell lymphomas by methylseleninic acid involves nuclear factor-kappaB inhibition and the rapid generation of other selenium species. Cancer Res vol. 67, (22) 10984-10992.
10.1158/0008-5472.CAN-07-0519
Owen C, Stevens J, Amess J, Chaplin T, Cavenagh J, Lillington D, Young BD, Lister TA et al. (2007). Familial myelodysplasia with monosomy 7. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL. vol. 92, 234-234.
Kakkas I, Summers K, Fleischmann C, Virappane P, Lister TA, Fitzgibbon J (2007). Simultaneous detection of FLT3, NPM1 and WT1 mutations using high-resolution capillary electrophoresis. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL. vol. 92, 370-370.
Virappane P, Gale RE, Hills RK, Kakkas K, Summers K, Stevens J, Green CL, Allen CG et al. (2007). Wilms' tumour 1 mutation in normal karyotype aml. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL. vol. 92, 19-20.
Juliger S, Joel SP, Fitzgibbon J, Lister TA (2007). Serum selenium at presentation may predict disease outcome in acute myeloid leukaemia (AML). BRITISH JOURNAL OF HAEMATOLOGY. vol. 137, 65-65.
Davies AJ, Rosenwald A, Wright G, Lee A, Last KW, Weisenburger DD, Chan WC, Delabie J et al.(2007). Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms. BRIT J HAEMATOL vol. 136, (2) 286-293.
10.1111/j.1365-2141.2006.06439.x
Summers K, Stevens J, Kakkas I, Smith M, Smith LL, MacDougall F, Cavenagh J, Bonnet D et al.(2007). Wilms' tumour 1 mutations are associated with FLT3-ITD and failure of standard induction chemotherapy in patients with normal karyotype AML [1]. Leukemia vol. 21, (3) 550-551.
10.1038/sj.leu.2404514
Last K, Maharaj L, Perry J, Strauss S, Fitzgibbon J, Lister TA, Joel S(2006). The activity of methylated and non-methylated selenium species in lymphoma cell lines and primary tumours. ANN ONCOL vol. 17, (5) 773-779.
10.1093/annonc/mdl004
Zhang LY, Smith ML, Schultheis B, Fitzgibbon J, Lister TA, Melo JV, Cross NCP, Cavenagh JD(2006). A novel K5091 mutation of KIT identified in familial mastocytosis - in vitro and in vivo responsiveness to imatinib therapy. LEUKEMIA RES vol. 30, (4) 373-378.
10.1016/j.leukres.2005.08.015
Smith LL, Pearce D, Smith ML, Jenner M, Lister TA, Bonnet D, Goff L, Fitzgibbon J(2006). Development of a quantitative real-time polymerase chain reaction method for monitoring CEBPA mutations in normal karyotype acute myeloid leukaemia. BRIT J HAEMATOL vol. 133, (1) 103-105.
10.1111/j.1365-2141.2006.06001.x
Juliger S, Goenaga-Infante H, Fitzgibbon J, Lister AT, Joel SP (2005). Methylseleninic acid results in rapid changes in intracellular selenium species and sensitises human lymphoma cells to doxorubicin. BLOOD. vol. 106, 503A-503A.
Joel SP, Oke A, Foot N, Keen N, Bonnet D, Lister TA, Fitzgibbon J (2005). The activity of the novel aurora kinase B inhibitor AZD1152 in acute myeloid leukaemia cells. BLOOD. vol. 106, 943A-943A.
Fitzgibbon J, Smith L-L, Raghavan M, Smith ML, Debernardi S, Skoulakis S, Lillington D, Lister TA et al.(2005). Association between acquired uniparental disomy and homozygous gene mutation in acute myeloid leukemias. Cancer Res vol. 65, (20) 9152-9154.
10.1158/0008-5472.CAN-05-2017
Smith LL, Smith M, Goff L, Jenner M, Lister A, Fitzgibbon J, Bonnett D (2005). Development of a quantitative real-time PCR method for monitoring CEBPA mutations in normal karyotype acute myeloid leukaemia patient samples. EXPERIMENTAL HEMATOLOGY. vol. 33, 73-73.
Davies A, Iqbal S, Fitzgibbon J, Raghavan M, Chaplin T, Norton A, Lister A, Young B (2005). Homozygosity mapping by genome-wide SNP analysis of the transformation of follicular lymphoma (FL) to diffuse large B-cell lymphoma (TxDLBCL). ANNALS OF ONCOLOGY. vol. 16, 106-106.
Davies A, Arch R, Goff L, Gesk S, Foot N, Rosenwald A, Dyer M, Marinez-Climent J et al. (2005). Refinement of the 13q31-32 amplicon in B-cell non-Hodgkin's lymphoma by a simultaneous genomic and transcriptional approach. ANNALS OF ONCOLOGY. vol. 16, 80-80.
Smith ML, Arch R, Smith L-L, Bainton N, Neat M, Taylor C, Bonnet D, Cavenagh JD et al.(2005). Development of a human acute myeloid leukaemia screening panel and consequent identification of novel gene mutation in FLT3 and CCND3. Br J Haematol vol. 128, (3) 318-323.
10.1111/j.1365-2141.2004.05324.x
Smith ML, Cavenagh JD, Lister TA, Fitzgibbon J(2004). Brief report - Mutation of CEBPA in familial acute myeloid leukemia. NEW ENGL J MED vol. 351, (23) 2403-2407.
10.1056/NEJMoa041331
Smith ML, Cavenagh JD, Lister TA, Fitzgibbon J(2004). Mutation of CEBPA in familial acute myeloid leukemia. N Engl J Med vol. 351, (23) 2403-2407.
10.1056/NEJMoa041331
Fitzgibbon J, Smith M, Arch R, Smith LL, Bainton N, Neat M, Bonnet D, Cavenagh J et al. (2004). Development of a human acute myeloid leukaemia screening panel and identification of novel gene mutations. BLOOD. vol. 104, 817A-817A.
Fitzgibbon J, Smith M, Cavenagh J, Lister TA (2004). Mutation of CEBPA in familial acute myeloid leukaemia. BLOOD. vol. 104, 555A-555A.
10.1182/blood.V104.11.2012.2012
Last K, Perry J, Maharaj L, Strauss S, Davies A, Skoulakis S, Fitzgibbon J, Lister A et al. (2004). The induction of apoptosis in lymphoma cells by methylseleninic acid and selenodiglutathione. BLOOD. vol. 104, 686A-686A.
10.1182/blood.V104.11.2502.2502
Last KW, Rohatiner AZS, Fitzgibbon J, Lister TA(2004). Serum selenium in lymphoma - In reply. J CLIN ONCOL vol. 22, (16) 3430-3430.
10.1200/JCO.2004.99.131
Nilsen H, An Q, Fitzgibbon J, Lister A, Lindahl T (2004). Complex phenotypes associated with uracil in DNA in mammals. BRITISH JOURNAL OF CANCER. vol. 91, S71-S71.
Iqbal S, Jenner MJR, Summers KE, Davies AJ, Matthews J, Norton AJ, Calaminici M, Rohatiner AZ et al.(2004). Reliable detection of clonal IgH/Bcl2 MBR rearrangement in follicular lymphoma: methodology and clinical significance. Br J Haematol vol. 124, (3) 325-328.
10.1046/j.1365-2141.2003.04796.x
Goff LK, Iqbal S, Jenner MJ, Summers KE, Matthews J, Norton AJ, Calaminici M, Rohatiner AZS et al. (2003). Reliable detection of clonal IgH/Bcl-2 MBR rearrangement in follicular lymphoma: Methodology and clinical significance. BLOOD. vol. 102, 633A-633A.
Debernardi S, Van Delft F, Davies A, Lillington D, Smith M, Lister TA, Saha V, Young BD et al. (2003). The Wiskott-Aldrich-Syndrome family member 1 (WASF1) gene on 6q21 is down-regulated in specific AML cytogenetic subtypes. BLOOD. vol. 102, 582A-582A.
Last KW, Cornelius V, Delves T, Sieniawska C, Fitzgibbon J, Norton A, Amess J, Wilson A et al.(2003). Presentation serum selenium predicts for overall survival, dose delivery, and first treatment response in aggressive non-Hodgkin's lymphoma. J Clin Oncol vol. 21, (12) 2335-2341.
10.1200/JCO.2003.06.145
Snaddon J, Smith ML, Neat M, Cambal-Parrales M, Dixon-McIver A, Arch R, Amess JA, Rohatiner AZ et al.(2003). Mutations of CEBPA in acute myeloid leukemia FAB types M1 and M2. Genes Chromosomes Cancer vol. 37, (1) 72-78.
10.1002/gcc.10185
Smith ML, Snaddon J, Neat M, Cambal-Parrales M, Arch R, Lister TA, Fitzgibbon J(2003). Mutation of BRAF is uncommon in AML FAB type M1 and M2. LEUKEMIA vol. 17, (1) 274-275.
10.1038/sj.leu.2402787
Davies A, Rosenwald A, Wright G, Henrickson SE, Hong Z, Fitzgibbon J, Last K, Norton A et al. (2002). Gene expression profiling in paired follicular lymphoma samples pre- and post-transformation to large B cell lymphoma. BLOOD. vol. 100, 315A-316A.
Jenner M, Summers K, Matthews J, Bradburn M, Dunning A, Wilson G, Lister TA, Fitzgibbon J (2002). Genetic risk factor for follicular lymphoma within the MHC region. BLOOD. vol. 100, 567A-567A.
Fitzgibbon J, Arch R, Davies A, Snaddon J, Neat M, Foot N, Summers K, Goff L et al. (2002). Refinement and evaluation of candidate genes within the 13q amplicon in germinal centre lymphoma. BLOOD. vol. 100, 189B-190B.
Jenner MJ, Summers KE, Norton AJ, Amess JA, Arch RS, Young BD, Lister TA, Fitzgibbon J et al.(2002). JH probe real-time quantitative polymerase chain reaction assay for Bcl-2/IgH rearrangements. Br J Haematol vol. 118, (2) 550-558.
10.1046/j.1365-2141.2002.03623.x
Summers KE, Davies AJ, Matthews J, Jenner MJ, Cornelius V, Amess JA, Norton AJ, Rohatiner AZS et al.(2002). The relative role of peripheral blood and bone marrow for monitoring molecular evidence of disease in follicular lymphoma by quantitative real-time polymerase chain reaction. Br J Haematol vol. 118, (2) 563-566.
10.1046/j.1365-2141.2002.03641.x
Snaddon J, Neat M, Fitzgibbon J, Smith ML, Rohatiner AZ, Lister TA, Amess JA(2002). Mutations in the runt homology domain of CBFalpha2 in myeloid malignancies with acquired trisomy 21. Cancer Genet Cytogenet vol. 136, (2) 151-152.
10.1016/s0165-4608(02)00525-3
Summers KE, Goff LK, Wilson AG, Gupta RK, Lister TA, Fitzgibbon J(2001). The frequency of the Bcl-2/IgH t(14;18)(q32;q21) rearrangement in normal individuals implications for the monitoring of disease in patients with follicular lymphoma. LEUKEMIA vol. 15, (12) 2024-2024.
Jenner MJ, Summers KE, Norton AJ, Amess JA, Arch RS, Young BD, Lister TA, Fitzgibbon J et al.(2001). A universal strategy for quantifying Bcl-2/IgH breakpoints in follicular lymphoma. BLOOD vol. 98, (11) 126A-126A.
Snaddon J, Arch R, Sutcliffe K, Lister TA, Fitzgibbon J(2001). Identification of several novel polymorphisms in the low affinity FC inhibitory receptor FCGR2B. BLOOD vol. 98, (11) 164B-164B.
Snaddon J, Neat M, Smith ML, Rohatiner AZ, Lister TA, Fitzgibbon J(2001). Mutations in the runt domain of CBFA2 in myeloid malignancies with acquired trisomy 21. BLOOD vol. 98, (11) 195B-195B.
Snaddon J, Smith ML, Neat M, Arch R, Cambal-Parrales M, Amess JA, Rohatiner AZ, Lister TA et al.(2001). Mutations of CEBPA in acute myeloid leukaemia FAB-type M1 and M2. BLOOD vol. 98, (11) 195B-195B.
Davies AJ, Summers KE, Matthews J, Jenner MJ, Amess JA, Norton AJ, Rohatiner AZ, Fitzgibbon J et al.(2001). The relative role of peripheral blood and bone marrow for monitoring molecular evidence of disease in follicular lymphoma by quantitative real time PCR. BLOOD vol. 98, (11) 124A-125A.
Neat MJ, Foot N, Jenner M, Goff L, Ashcroft K, Burford D, Dunham A, Norton A et al.(2001). Localisation of a novel region of recurrent amplification in, follicular lymphoma to an similar to 6.8 Mb region of 13q32-33. GENE CHROMOSOME CANC vol. 32, (3) 236-243.
10.1002/gcc.1187
Foot N, Neat M, Jenner M, Goff L, Dunham I, Ross M, Fitzgibbon J, Lister TA(2001). Localisation of a novel region of amplification in follicular lymphoma tumours to a 24cR region of human chromosome 13. J MED GENET vol. 38, S44-S44.
Last KW, Cornelius V, Delves T, Fitzgibbon J, Wilson A, Rohatiner AZS, Lister TA(2001). Presentation serum selenium predicts for overall survival in patients with diffuse large B-cell (DLBC) lymphoma. BRIT J CANCER vol. 85, 59-59.
Summers KE, Goff LK, Wilson AG, Gupta RK, Lister TA, Fitzgibbon J(2001). Frequency of the Bcl-2/IgH rearrangement in normal individuals: implications for the monitoring of disease in patients with follicular lymphoma. J Clin Oncol vol. 19, (2) 420-424.
10.1200/JCO.2001.19.2.420
Jenner MJ, Matthews J, Summers K, Young BD, Fitzgibbon J, Lister A(2000). Application of real time PCR to establishing clonality of Bcl-2 rearrangements in patients with follicular lymphoma. BLOOD vol. 96, (11) 332A-332A.
Fitzgibbon J, Hill AS, Arch RS, Sutcliffe C, Summers KE, Lister A(2000). Identification of a novel polymorphism in the human FCGR2B gene: Correlation with response to Rituximab treatment in patients with follicular lymphoma. BLOOD vol. 96, (11) 179B-179B.
Neat M, Foot N, Jenner M, Goff L, Ashcroft K, Burford D, Dunham A, Fitzgibbon J et al.(2000). Localisation of a novel region of amplification in follicular lymphoma to an similar to 6.8 Mb region of human chromosome 13q32-33. BLOOD vol. 96, (11) 87A-87A.
Last KW, Cornelius VR, Delves T, Fitzgibbon J, Wilson A, Rohatiner AZ, Lister A(2000). Presentation serum selenium predicts for overall survival in patients with diffuse large B-cell (DLBC) lymphoma. BLOOD vol. 96, (11) 335A-335A.
Halford S, Dulai KS, Daw SC, Fitzgibbon J, Hunt DM(1998). Isolation and chromosomal localization of two human CDP-diacylglycerol synthase (CDS) genes. Genomics vol. 54, (1) 140-144.
10.1006/geno.1998.5547
Return to top